+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The End of Alzheimer's. Edition No. 2

  • ID: 3980667
  • Book
  • 482 Pages
  • Elsevier Science and Technology
1 of 4

The End of Alzheimer's: The Brain and Beyond, Second Edition is the first comprehensive overview on the molecular basis of Alzheimer's outside of the brain, merging the most recent findings within the field into a single book. It aims to educate the reader on the many overlooked aspects of Alzheimer's disease that occur outside the brain.

This book uniquely provides step-by-step, peer-reviewed evidence that the current research model may be misguided and that a new and emerging model is more accurate. It carefully outlines the molecular research in Alzheimer's outside the brain and argues that a more thorough, whole-body diagnosis will provide better answers about its causes and lead to new treatments.

It is beneficial to researchers who need to be apprised of the emerging science on the causes of Alzheimer's, and will hopefully redirect many into new avenues of cellular research and discovery.

  • Comprehensive literature-based summary of the current state of molecular Alzheimer's disease research
  • Details the shortcomings of the prevailing model and therapeutics in development
  • Reviews blood-based biomarkers for Alzheimer's and their link to amyloid- and Tau-independent causes outside the brain
  • Describes the tissues outside the brain impacted by Alzheimer's and the underlying molecular causes
  • Explains the whole-body risks associated with Alzheimer's, along with concomitant measures to slow or prevent the disease
  • Provides a protocol to properly research, evaluate, measure, diagnose, and potentially treat Alzheimer's patients

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 4

1. Is it Alzheimer's? 2. The Amyloid Cascade Hypothesis3. Diagnosis of Alzheimer's 4. Molecular Causes and Research5. Can Medicine Save You?6. A New Diagnostic Paradigm
The Molecular Eye7. Inflammation
Friend or Foe?8. Alzheimer's Beyond the Brain
Molecular Research in the Body 9. Does Infection Cause Alzheimer's? 10. Alzheimer's Disease Prevention 11. Differential Diagnosis toward a Cure for Alzheimer's

Appendix 1: Signs, symptoms, and stages of Alzheimer's 2: Alzheimer's Research at the Cellular Level 3: Concept of a Medical "Cure" 4: Alzheimer's Disease Statistics 5: Eye and Whole Body Diseases

Note: Product cover images may vary from those shown
3 of 4


4 of 4
Lewis, Thomas J.
Dr. Lewis is an inorganic and physical chemist with degrees from Worcester Polytechnic Institute (WPI) and the Massachusetts Institute of Technology (MIT). In addition to a Ph.D., Dr. Lewis has training from the Harvard School of Public Health in Toxicology, Industrial Hygiene, and a certificate in Industrial Hygiene from the University of Massachusetts. Fundamentally Dr. Lewis is a medical researcher and medical information translator. Much of his knowledge comes for the clinical work of Dr. Clement L. Trempe and Dr. Kilmer McCully. These clinicians are pioneers in systemic chronic diseases, disease detection using ocular biomarkers, germ theory, inflammatory diseases, and micronutrient balance in immune health. He is the founder of the RealHealth companies including RealHealth Clinics. Dr. Lewis is also engaged in developing new small molecule therapeutics for the treatment of diseases of aging, with special focus on Alzheimer's disease. Dr. Lewis holds patents (pending) on novel approaches to treat cancer and methods and approaches for treating chronic diseases of aging, including Alzheimer's disease and macular degeneration. In addition, he has patents pending on a new risk calculator for chronic disease which he has trademarked "chronic disease temperature(tm)."
Trempe, Clement L.
Dr. Trempe received his MD degree from Ottawa Medical School, Canada. He furthered his studies at Harvard's Schepens Eye Research Institute (SERI) and Massachusetts Eye and Ear Infirmary, Boston. He has been on staff at Harvard Medical School teaching hospitals since the 1970s. Dr. Trempe didn't set out to solve the Alzheimer's conundrum, he instead set out to treat eye diseases in a different way: treat the causes of the sick body and the health of the eye will also improve. When Dr. Trempe started diagnosing and treating his "eye” patients for systemic diseases, their eyes got better and stayed much better compared to people who were treated as if their eyes existed in isolation from the rest of the body. This multidisciplinary approach resulted in many patients with serious disease beyond the eye reporting that their other conditions improved upon Dr. Trempe's "eye” (whole body) treatments. One of those conditions that improved was Alzheimer's disease. His medical career at Harvard Medical School has spanned five decades. He is the author of hundreds of medical/scientific papers, two pending patents, and two books.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3980667